I kliniske undersøgelser med infliximab blev der observeret bivirkninger hos cirka 60% af infliximabbehandlede patienter og 40% af placebobehandlede patienter.
In clinical studies with infliximab, adverse reactions were observed in approximately 60% of infliximab-treated patients and 40% of placebo-treated patients.